2024
Late Cardiac Toxic Effects Associated With Treatment Protocols for Hodgkin Lymphoma in Children
Lo A, Liu A, Liu Q, Yasui Y, Castellino S, Kelly K, Hererra A, Friedberg J, Friedman D, Schwartz C, Pei Q, Kessel S, Bergeron-Gravel S, Dama H, Roberts K, Constine L, Hodgson D. Late Cardiac Toxic Effects Associated With Treatment Protocols for Hodgkin Lymphoma in Children. JAMA Network Open 2024, 7: e2351062. PMID: 38241048, PMCID: PMC10799264, DOI: 10.1001/jamanetworkopen.2023.51062.Peer-Reviewed Original ResearchConceptsCardiac toxic effectsMediastinal RTHodgkin lymphomaRadiation therapyCumulative incidenceCardiac diseaseDoxorubicin doseCohort studyClinical trialsMedian mean heart doseChildren's Oncology Group clinical trialStudy populationHigh-risk HLMean heart dosePlanned cumulative doseRadiation therapy useIncidence of cardiac diseaseCumulative doxorubicin doseRisks associated with treatmentNorth American trialsGroup clinical trialFollow-up guidelinesStandard treatment groupToxic effectsMaintained long term
2023
Prognostic value of chest x‐ray‐ and CT‐defined large mediastinal adenopathy in high‐risk pediatric Hodgkin lymphoma: A report from the Children's Oncology Group Study AHOD0831
Lo A, Lee I, Pei Q, Wu Y, McCarten K, Hoppe B, Hodgson D, Roberts K, Milgrom S, Kessel S, Cole P, Kelly K, Cho S. Prognostic value of chest x‐ray‐ and CT‐defined large mediastinal adenopathy in high‐risk pediatric Hodgkin lymphoma: A report from the Children's Oncology Group Study AHOD0831. Pediatric Blood & Cancer 2023, 70: e30452. PMID: 37243975, PMCID: PMC10546608, DOI: 10.1002/pbc.30452.Peer-Reviewed Original ResearchConceptsRelapse-free survivalLarge mediastinal adenopathySlow early responseInferior relapse-free survivalWorse relapse-free survivalMediastinal mass ratioPediatric Hodgkin lymphomaHodgkin's lymphomaMediastinal adenopathyPrognostic valueAdvanced-stage HL patientsChildren's Oncology Group studyChest X-rayHazard ratioHL patientsMedian agePoor prognosisChest radiographsMass volumeMass diameterPatientsML/Group studyCTEarly responseRadiation Therapy Use in Refractory and Relapsed Adolescent and Young Adult Hodgkin Lymphoma: A Report from the Children's Oncology Group
Mailhot Vega R, Harker-Murray P, Forlenza C, Cole P, Kelly K, Milgrom S, Parikh R, Hodgson D, Castellino S, Kahn J, Roberts K, Constine L, Hoppe B. Radiation Therapy Use in Refractory and Relapsed Adolescent and Young Adult Hodgkin Lymphoma: A Report from the Children's Oncology Group. International Journal Of Radiation Oncology • Biology • Physics 2023, 117: 400-403. PMID: 37116589, PMCID: PMC10655744, DOI: 10.1016/j.ijrobp.2023.04.022.Peer-Reviewed Original ResearchBaseline metabolic tumour burden improves risk stratification in Hodgkin lymphoma: A Children's Oncology Group study
Milgrom S, Kim J, Pei Q, Lee I, Hoppe B, Wu Y, Hodgson D, Kessel S, McCarten K, Roberts K, Lo A, Cole P, Kelly K, Cho S. Baseline metabolic tumour burden improves risk stratification in Hodgkin lymphoma: A Children's Oncology Group study. British Journal Of Haematology 2023, 201: 1192-1199. PMID: 36922022, PMCID: PMC10247420, DOI: 10.1111/bjh.18734.Peer-Reviewed Original ResearchConceptsRapid early respondersEvent-free survivalTotal lesion glycolysisBaseline total lesion glycolysisIntensive therapyRisk stratificationTumor burdenHodgkin's lymphomaEarly respondersMTV/TLGFour-year event-free survivalBaseline metabolic tumor burdenExcellent event-free survivalHigh-risk Hodgkin lymphomaChildren's Oncology Group studyPoor event-free survivalMaximum standardized uptake valueResponse-adapted approachBaseline PET scanMetabolic tumor burdenStandardized uptake valueIntensified therapyLesion glycolysisBaseline PETTumor SUVImportance of Central Imaging Review in a Pediatric Hodgkin Lymphoma Trial Using Positron Emission Tomography Response Adapted Radiation Therapy
Hoppe B, McCarten K, Pei Q, Kessel S, Alazraki A, Mhlanga J, Lai H, Eutsler E, Hodgson D, Roberts K, Charpentier A, Keller F, Voss S, Wu Y, Cho S, Kelly K, Castellino S. Importance of Central Imaging Review in a Pediatric Hodgkin Lymphoma Trial Using Positron Emission Tomography Response Adapted Radiation Therapy. International Journal Of Radiation Oncology • Biology • Physics 2023, 116: 1025-1030. PMID: 36868525, PMCID: PMC10363760, DOI: 10.1016/j.ijrobp.2023.02.020.Peer-Reviewed Original ResearchMeSH KeywordsChildFluorodeoxyglucose F18Hodgkin DiseaseHumansPositron Emission Tomography Computed TomographyPositron-Emission TomographyConceptsCentral reviewDeauville scoreCentral imaging reviewRadiation therapyResponse assessmentHodgkin's lymphomaImaging reviewInstitutional reviewFluorodeoxyglucose positron emission tomography/High-risk Hodgkin lymphomaPositron emission tomography responseConcordance rateEmission tomography/Real-time central reviewCohen κ statisticAreas of diseaseSystemic therapyTreating institutionPediatric patientsLymphoma trialsTomography responseTomography/Treatment allocationClinical trialsPatients
2021
Patterns of Initial Relapse from a Phase 3 Study of Response-Based Therapy for High-Risk Hodgkin Lymphoma (AHOD0831): A Report from the Children's Oncology Group
Parikh RR, Kelly KM, Hodgson DC, Hoppe BS, McCarten KM, Karolczuk K, Pei Q, Wu Y, Cho SY, Schwartz C, Cole PD, Roberts K. Patterns of Initial Relapse from a Phase 3 Study of Response-Based Therapy for High-Risk Hodgkin Lymphoma (AHOD0831): A Report from the Children's Oncology Group. International Journal Of Radiation Oncology • Biology • Physics 2021, 112: 890-900. PMID: 34767937, PMCID: PMC9038118, DOI: 10.1016/j.ijrobp.2021.10.152.Peer-Reviewed Original ResearchConceptsInvolved-field radiation therapySlow early responseClassical Hodgkin lymphomaBulky diseaseOncology GroupHodgkin's lymphomaRetrospective analysisChildren's Oncology Group protocolsHigh-risk Hodgkin lymphomaRadiation treatment volumesCycles of doxorubicinHigh-risk patientsPhase 3 studyTime of progressionChildren's Oncology GroupPatterns of failureInitial siteABVE-PCConsolidation RTEligible patientsField relapseInitial relapseMedian followRelapse siteStage IIIBPediatric Hodgkin Lymphoma, Version 3.2021.
Flerlage J, Hiniker S, Armenian S, Benya E, Bobbey A, Chang V, Cooper S, Coulter D, Cuglievan B, Hoppe B, Isenalumhe L, Kelly K, Kersun L, Lamble A, Larrier N, Magee J, Oduro K, Pacheco M, Price A, Roberts K, Smith C, Sohani A, Trovillion E, Walling E, Xavier A, Burns J, Campbell M. Pediatric Hodgkin Lymphoma, Version 3.2021. Journal Of The National Comprehensive Cancer Network 2021, 19: 733-754. PMID: 34214968, DOI: 10.6004/jnccn.2021.0027.Peer-Reviewed Original ResearchConceptsPediatric Hodgkin lymphomaClassic Hodgkin lymphomaHodgkin's lymphomaNCCN Clinical Practice GuidelinesClinical practice guidelinesCurrent treatment regimensNCCN guidelinesRefractory settingSystemic therapyCurable formTreatment regimensPrinciples of pathologyDiagnostic evaluationLate effectsPractice guidelinesRadiation therapyTreatment efficacyLymphomaTherapyTreatmentGuidelinesRegimensWorkupCancerStagingPediatric classical Hodgkin lymphoma
Lo AC, Dieckmann K, Pelz T, Gallop‐Evans E, Engenhart‐Cabillic R, Vordermark D, Kelly KM, Schwartz CL, Constine LS, Roberts K, Hodgson D. Pediatric classical Hodgkin lymphoma. Pediatric Blood & Cancer 2021, 68: e28562. PMID: 33818890, DOI: 10.1002/pbc.28562.Peer-Reviewed Original ResearchConceptsClassical Hodgkin lymphomaChildren's Oncology GroupPediatric classical Hodgkin lymphomaHodgkin's lymphomaRadiation therapyOncology GroupUtilization of RTHigh-risk patientsBulk of diseaseHigh cure ratesUniformly fatal diseaseLong-term toxicityIntensity of treatmentEuroNet-PHLB symptomsRisk patientsCurable cancerLymphoma trialsRT volumeCure rateTumor stageImmunoregulatory drugsTrial groupChemotherapy agentsHL management
2020
Nodular lymphocyte predominant Hodgkin lymphoma: executive summary of the American radium society appropriate use criteria
Ballas LK, Metzger ML, Milgrom SA, Advani R, Bakst RL, Dabaja BS, Flowers CR, Ha CS, Hoppe BS, Mansur DB, Pinnix CC, Plastaras JP, Roberts KB, Smith SM, Terezakis SA, Constine LS. Nodular lymphocyte predominant Hodgkin lymphoma: executive summary of the American radium society appropriate use criteria. Leukemia & Lymphoma 2020, 62: 1057-1065. PMID: 33274673, DOI: 10.1080/10428194.2020.1852559.Peer-Reviewed Original ResearchConceptsNodular lymphocyte predominant Hodgkin lymphomaHodgkin's lymphomaAmerican Radium Society Appropriate Use CriteriaLymphocyte predominant Hodgkin lymphomaAppropriate use criteriaMultidisciplinary expert panelPredominant Hodgkin lymphomaClassical Hodgkin lymphomaRare lymphomaClinical variantsAmerican Radium SocietyConsensus recommendationsGuideline developmentRadiation oncologistsLymphomaStrong recommendationsCompelling dataConsensus methodologyUse criteriaExpert panelExpert opinionExecutive summaryLiterature reviewGuidelinesPatientsStage I-II nodular lymphocyte-predominant Hodgkin lymphoma: a multi-institutional study of adult patients by ILROG
Binkley M, Rauf M, Milgrom S, Pinnix C, Tsang R, Dickinson M, Ng A, Roberts K, Gao S, Balogh A, Ricardi U, Levis M, Casulo C, Stolten M, Specht L, Plastaras J, Wright C, Kelsey C, Brady J, Mikhaeel N, Hoppe B, Terezakis S, Picardi M, Della Pepa R, Kirova Y, Akhtar S, Maghfoor I, Koenig J, Jackson C, Song E, Sehgal S, Advani R, Natkunam Y, Constine L, Eich H, Wirth A, Hoppe R. Stage I-II nodular lymphocyte-predominant Hodgkin lymphoma: a multi-institutional study of adult patients by ILROG. Blood 2020, 135: 2365-2374. PMID: 32211877, DOI: 10.1182/blood.2019003877.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedCombined Modality TherapyFemaleFollow-Up StudiesHodgkin DiseaseHumansKaplan-Meier EstimateLymphoma, Large B-Cell, DiffuseMaleMiddle AgedNeoplasm StagingNeoplasms, Radiation-InducedNeoplasms, Second PrimaryPositron Emission Tomography Computed TomographyProgression-Free SurvivalProportional Hazards ModelsRecurrenceRetrospective StudiesSalvage TherapySurvival AnalysisTreatment OutcomeYoung AdultConceptsNodular lymphocyte-predominant Hodgkin lymphomaProgression-free survivalOverall survivalImmunoarchitectural patternsAssociated with worse progression-free survivalFive-year PFSLymphocyte-predominant Hodgkin lymphomaProgression-free survival ratesStudy of adult patientsSingle-agent rituximabLarge-cell transformationStage I diseaseMedian follow-upMulticenter retrospective studyMulti-institutional studyHodgkin lymphomaI diseaseRT cohortHistological variantsMedian agePrimary managementRetrospective studyRituximabAdult patientsRadiotherapy
2019
Response‐adapted therapy for the treatment of children with newly diagnosed high risk Hodgkin lymphoma (AHOD0831): a report from the Children’s Oncology Group
Kelly KM, Cole PD, Pei Q, Bush R, Roberts KB, Hodgson DC, McCarten KM, Cho SY, Schwartz C. Response‐adapted therapy for the treatment of children with newly diagnosed high risk Hodgkin lymphoma (AHOD0831): a report from the Children’s Oncology Group. British Journal Of Haematology 2019, 187: 39-48. PMID: 31180135, PMCID: PMC6857800, DOI: 10.1111/bjh.16014.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAntineoplastic Combined Chemotherapy ProtocolsBleomycinChildChild, PreschoolCyclophosphamideDoxorubicinDrug Administration ScheduleDrug MonitoringEtoposideFemaleHodgkin DiseaseHumansIfosfamideMaleNeoplasm StagingPositron-Emission TomographyPrednisoneProspective StudiesRadiotherapy, AdjuvantRecurrenceTreatment OutcomeVincristineVinorelbineYoung AdultConceptsHigh-risk Hodgkin lymphomaABVE-PCOncology GroupHodgkin's lymphomaEarly respondersRapid early respondersEnd of chemotherapyEvent-free survivalOverall survival rateResponse-adapted therapyChildren's Oncology GroupTreatment of childrenPET-positive lesionsAlkylator exposureOS ratesActive diseaseTreat analysisPediatric patientsRadiotherapy volumeClinical evidenceEarly progressionRadiation volumeRecent trialsPositive lesionsSER patients
2016
ACR Appropriateness Criteria® Recurrent Hodgkin Lymphoma.
Winkfield KM, Advani RH, Ballas LK, Dabaja BS, Dhakal S, Flowers CR, Ha CS, Hoppe BS, Mansur DB, Mendenhall NP, Metzger ML, Plastaras JP, Roberts KB, Shapiro R, Smith SM, Terezakis SA, Younes A, Constine LS. ACR Appropriateness Criteria® Recurrent Hodgkin Lymphoma. Oncology 2016, 30: 1099-103, 1106-8. PMID: 27987203, PMCID: PMC7440297.Peer-Reviewed Original ResearchConceptsRecurrent Hodgkin lymphomaHodgkin's lymphomaAppropriateness CriteriaAutologous stem cell transplantationMedical literatureAppropriateness of imagingInnovative targeted therapiesCombined-modality therapyLow-dose therapyACR Appropriateness CriteriaEarly-stage diseaseStem cell transplantationMultidisciplinary expert panelRadiology Appropriateness CriteriaEvidence-based guidelinesSpecific clinical conditionsSpecific clinical scenariosCurrent medical literatureRecent medical literaturePeer-reviewed journalsRecurrent diseaseSalvage optionCell transplantationTargeted therapyClinical conditionsACR Appropriateness Criteria® Hodgkin Lymphoma-Favorable Prognosis Stage I and II
Dhakal S, Advani R, Ballas LK, Dabaja BS, Flowers CR, Ha CS, Hoppe BS, Mendenhall NP, Metzger ML, Plastaras JP, Roberts KB, Shapiro R, Smith SM, Terezakis SA, Winkfield KM, Younes A, Constine LS. ACR Appropriateness Criteria® Hodgkin Lymphoma-Favorable Prognosis Stage I and II. American Journal Of Clinical Oncology 2016, 39: 535-544. PMID: 27643717, PMCID: PMC7433865, DOI: 10.1097/coc.0000000000000331.Peer-Reviewed Original ResearchMeSH KeywordsAdultAntineoplastic Combined Chemotherapy ProtocolsChemoradiotherapyDisease-Free SurvivalDose-Response Relationship, DrugFemaleHodgkin DiseaseHumansMaleNeoplasm InvasivenessNeoplasm StagingOutcome Assessment, Health CarePractice Guidelines as TopicRadiotherapy DosageRandomized Controlled Trials as TopicRisk AssessmentSocieties, MedicalSurvival AnalysisUnited StatesConceptsStage IModality therapyHodgkin's lymphomaAppropriateness CriteriaMedical literatureAppropriateness of imagingACR Appropriateness CriteriaRadiology Appropriateness CriteriaEvidence-based guidelinesMultidisciplinary expert panelSpecific clinical conditionsSpecific clinical scenariosCurrent medical literatureRecent medical literatureLess chemotherapyPeer-reviewed journalsLate effectsClinical conditionsRadiation therapyAmerican CollegeExpert opinionClinical scenariosExcellent efficacyGuideline developmentAvailable evidenceACR Appropriateness Criteria® Hodgkin Lymphoma—Unfavorable Clinical Stage I and II
Roberts KB, Younes A, Hodgson DC, Advani R, Dabaja BS, Dhakal S, Flowers CR, Ha CS, Hoppe BS, Mendenhall NP, Metzger ML, Plastaras JP, Shapiro R, Smith SM, Terezakis SA, Winkfield KM, Constine LS. ACR Appropriateness Criteria® Hodgkin Lymphoma—Unfavorable Clinical Stage I and II. American Journal Of Clinical Oncology 2016, 39: 384-395. PMID: 27299425, DOI: 10.1097/coc.0000000000000294.Peer-Reviewed Original ResearchConceptsHodgkin's lymphomaAppropriateness CriteriaEvidence-based treatment algorithmEarly-stage Hodgkin lymphomaAppropriateness of imagingClinical stage IRadiation treatment volumesMajor clinical trialsACR Appropriateness CriteriaRadiology Appropriateness CriteriaMultidisciplinary expert panelEvidence-based guidelinesClassic Hodgkin lymphomaInvolved-site radiotherapySpecific clinical conditionsCurrent medical literatureAppropriate treatment decisionsLong-term toxicityCurrent treatment schemesRadiation dose prescriptionUnfavorable presentationSequential chemotherapyPeer-reviewed journalsPrognostic factorsTherapy intensity
2014
ACR Appropriateness Criteria Follow-up of Hodgkin Lymphoma
Ha CS, Hodgson DC, Advani R, Dabaja BS, Dhakal S, Flowers CR, Hoppe BS, Mendenhall NP, Metzger ML, Plastaras JP, Roberts KB, Shapiro R, Smith S, Terezakis SA, Winkfield KM, Younes A, Constine LS. ACR Appropriateness Criteria Follow-up of Hodgkin Lymphoma. Journal Of The American College Of Radiology 2014, 11: 1026-1033.e3. PMID: 25278496, DOI: 10.1016/j.jacr.2014.07.038.Peer-Reviewed Original ResearchConceptsLong-term sequelaeDetection of recurrenceHodgkin's lymphomaPhysical examinationRoutine surveillance CT scanSequelae of treatmentAppropriateness of imagingMajority of recurrencesACR Appropriateness CriteriaSurveillance CT scansRoutine imaging studiesCompletion of treatmentEvidence-based guidelinesMultidisciplinary expert panelSpecific clinical conditionsCurrent medical literatureVolume of radiationSalvage therapyPeer-reviewed journalsSecondary malignanciesBlood testsAppropriateness CriteriaFollow-upCardiovascular diseaseReproductive dysfunctionACR appropriateness Criteria® pediatric Hodgkin lymphoma
Terezakis SA, Metzger ML, Hodgson DC, Schwartz CL, Advani R, Flowers CR, Hoppe BS, Ng A, Roberts KB, Shapiro R, Wilder RB, Yunes MJ, Constine LS. ACR appropriateness Criteria® pediatric Hodgkin lymphoma. Pediatric Blood & Cancer 2014, 61: 1305-1312. PMID: 24616347, DOI: 10.1002/pbc.24983.Peer-Reviewed Original ResearchConceptsPediatric Hodgkin lymphomaHodgkin's lymphomaAppropriateness CriteriaAppropriateness of imagingACR Appropriateness CriteriaExpert panelMultidisciplinary expert panelRadiology Appropriateness CriteriaEvidence-based guidelinesCommon clinical scenariosSpecific clinical conditionsCurrent medical literaturePotential long-term effectsCurable malignancyExpert medical opinionClinical variantsClinical conditionsLong-term effectsAmerican CollegeClinical careTherapy needTreatment approachesGuideline developmentClinical scenariosLymphoma
2012
Historical Trends in the Use of Radiation Therapy for Pediatric Cancers: 1973-2008
Jairam V, Roberts KB, Yu JB. Historical Trends in the Use of Radiation Therapy for Pediatric Cancers: 1973-2008. International Journal Of Radiation Oncology • Biology • Physics 2012, 85: e151-e155. PMID: 23273995, PMCID: PMC3636568, DOI: 10.1016/j.ijrobp.2012.10.007.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentBone NeoplasmsChildChild, PreschoolFemaleHodgkin DiseaseHumansInfantInfant, NewbornLeukemia, Myeloid, AcuteLymphoma, Non-HodgkinMaleNeoplasmsNeuroblastomaOsteosarcomaPrecursor Cell Lymphoblastic Leukemia-LymphomaRadiotherapyRetinoblastomaSEER ProgramSoft Tissue NeoplasmsTime FactorsUnited StatesWilms TumorYoung AdultConceptsUse of RTSoft tissue cancerNon-Hodgkin lymphomaRT useAcute lymphoblastic leukemiaAcute myeloid leukemiaRadiation therapyHodgkin's lymphomaLymphoblastic leukemiaMyeloid leukemiaWilms tumorBrain cancerNational Cancer Institute's SurveillanceExternal beam radiation therapyEnd Results (SEER) databasePercentage of patientsSEER 9 databaseBeam radiation therapyTumor RegistryInitial treatmentResults databaseCombination therapyDiagnosis groupsPediatric cancerJoint cancerPatterns of subsequent malignancies after Hodgkin lymphoma in children and adults
Omer B, Kadan‐Lottick N, Roberts KB, Wang R, Demsky C, Kupfer GM, Cooper D, Seropian S, Ma X. Patterns of subsequent malignancies after Hodgkin lymphoma in children and adults. British Journal Of Haematology 2012, 158: 615-625. PMID: 22775513, DOI: 10.1111/j.1365-2141.2012.09211.x.Peer-Reviewed Original ResearchConceptsSecond malignant neoplasmsStandardized incidence ratiosSolid second malignant neoplasmsExtended field radiotherapyRecent treatment optionsLow-dose radiationSMN riskSubsequent malignanciesModality therapyIncidence ratiosHodgkin's lymphomaTreatment optionsMalignant neoplasmsSubgroup analysisCMT groupLower incidenceHigh riskGeneral populationAlkylator chemotherapyPatientsDose radiationRiskRadiotherapyChildrenAdults
2000
Radiation dose selection in Hodgkin’s disease patients with large mediastinal adenopathy treated with combined modality therapy
Elconin J, Roberts K, Rizzieri D, Vermont C, Clough R, Kim C, Dodge R, Prosnitz L. Radiation dose selection in Hodgkin’s disease patients with large mediastinal adenopathy treated with combined modality therapy. International Journal Of Radiation Oncology • Biology • Physics 2000, 48: 1097-1105. PMID: 11072168, DOI: 10.1016/s0360-3016(00)00695-7.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAgedAged, 80 and overAntineoplastic Combined Chemotherapy ProtocolsBleomycinChildCombined Modality TherapyDacarbazineDisease-Free SurvivalDoxorubicinFemaleHodgkin DiseaseHumansMaleMechlorethamineMediastinal NeoplasmsMiddle AgedNeoplasm StagingPrednisoneProcarbazineRadiotherapy DosageRetrospective StudiesTreatment FailureVinblastineVincristineConceptsLarge mediastinal adenopathyHodgkin's disease patientsComplete responseDisease patientsInduction chemotherapyInduction failureGallium scanMediastinal adenopathyModality therapyRT doseComplete clinical stagingLow-dose radiotherapyResidual radiographic abnormalitiesCycles of chemotherapyFailure-free survivalPhase III trialsPatterns of failureConsolidation radiationChemotherapy regimensCR patientsIII trialsOverall survivalClinical stagingHD patientsRadiographic abnormalities
1996
Second solid tumors in patients with Hodgkin's disease cured after radiation or chemotherapy plus adjuvant low-dose radiation.
Salloum E, Doria R, Schubert W, Zelterman D, Holford T, Roberts K, Farber L, Kiehl R, Cardinale J, Cooper D. Second solid tumors in patients with Hodgkin's disease cured after radiation or chemotherapy plus adjuvant low-dose radiation. Journal Of Clinical Oncology 1996, 14: 2435-43. PMID: 8823321, DOI: 10.1200/jco.1996.14.9.2435.Peer-Reviewed Original ResearchConceptsOverall relative riskHodgkin's diseaseRT groupRelative riskSolid tumorsCMT groupRadiation therapyLung cancerBreast cancerEarly-stage Hodgkin's diseaseFull-dose radiation therapyInvolved-field radiationSecond solid tumorsConnecticut Tumor RegistryEarly-stage diseaseLong-term survivorsDifferent therapeutic approachesCases of lungLow-dose radiationSignificant increaseActuarial incidenceMedian followSalvage chemotherapyAdvanced diseaseDurable remissions